Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
NEW YORK, March 13, 2017 -- Chicago-based R1 RCM Inc. (OTC Pink:ACHI) (“R1” or the “Company”), a leading provider of revenue cycle management and physician advisory services to healthcare providers, announced today that it has received approval to list on the Nasdaq Capital Market effective at the opening of trading on Wednesday, March 15, 2017. Joe Flanagan, R1’s President and CEO, will ring the opening bell in honor of the occasion. The Company’s new stock symbol will be RCM (NASDAQ:RCM).
“Listing on Nasdaq is a key milestone for R1 and reflects the progress we continue to make as we embark on our next phase of growth,” said Flanagan. “We are thrilled to be listed on one of the most dynamic markets in the world and look forward to the opportunities this listing will provide.”
About R1 RCM
R1 serves as the one revenue cycle management partner for select hospitals and healthcare systems regardless of their payment models, partner engagement strategies, or settings of care. The company uses a proven operating model based on the R1 Performance StackSM designed to fit seamlessly into any healthcare organization’s infrastructure and to enhance the patient experience, improve provider economics, and provide revenue predictability. To learn more visit: r1rcm.com.
Contacts: R1 RCM Inc. Investor Relations: Atif Rahim 312-324-5476 [email protected] Media Relations: Deborah Lacy 650-814-7125 [email protected]
